Does Wegovy Have a Golden Dose Like Mounjaro?

Wegovy (semaglutide) and Mounjaro (tirzepatide) both follow a gradual titration schedule — starting at a low dose and increasing over several months under prescriber guidance. Where they differ is in their mechanism and dose structure.

Wegovy's five dose stages

Wegovy is typically titrated through a series of dose strengths — 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg — with each stage generally lasting several weeks before moving to the next, as directed by a prescriber. In that sense, Wegovy does have a fifth dose stage (2.4 mg), which is its maintenance dose. Whether this counts as a "fifth dose" in the way Mounjaro's titration is sometimes discussed is a matter of framing rather than pharmacology — you can read more about what the fifth dose means on Mounjaro for comparison.

Why a "golden dose" idea emerged with Mounjaro

The "golden dose" concept became popular in online communities around a specific Mounjaro strength where many people felt side effects had noticeably settled while results remained strong. Mounjaro's dual GIP and GLP-1 receptor agonist action means its side-effect profile can differ from Wegovy, which acts on GLP-1 receptors alone. This is one reason the two medicines are sometimes discussed in terms of whether Wegovy has its own golden dose equivalent.

Side effects: are they worse on one than the other?

Whether Wegovy has more side effects than Mounjaro — or fewer — varies considerably from person to person. Both medicines commonly cause gastrointestinal effects such as nausea, constipation, and indigestion, particularly during dose increases. Some people report that side effects on one medicine feel more manageable than the other; others find the opposite. These are individual responses, and no comparison between medicines should be used to influence a prescribing decision — that belongs with your prescriber or doctor, who knows your full history. For a factual side-by-side look at the two medicines, see how Mounjaro's doses and titration work as context.

According to NHS guidance, gastrointestinal side effects with GLP-1 receptor agonists are most common when a dose is first started or increased, and they often lessen as the body adjusts.

Whether you are working through Wegovy's titration stages or trying to identify a dose that feels most manageable for you, keeping a clear dose log is one of the most useful things you can do — both for your own awareness and for conversations with your prescriber.

GLP Trackr's dose logging feature lets you record each injection as it happens: the date, the dose strength, and how you felt in the days that followed. Over time, this creates a timeline that shows exactly where you were in your schedule when side effects were at their most noticeable — and when things started to ease. If you want to explore whether a particular stage felt like your own personal sweet spot, that pattern becomes visible in your data rather than relying on memory.

The side-effect tracking feature works alongside dose logging, so you can note symptoms like nausea or fatigue against specific doses. This kind of record is genuinely useful to bring to a prescriber appointment — the app's doctor report feature can summarise your journey in a clear format to share with your healthcare team.

Any decision about whether to stay at a dose, move up, or adjust your schedule is always one for your prescriber or doctor — they have the full clinical picture. GLP Trackr helps you record what you experience so those conversations are better informed, not a substitute for them.

If you are curious how the concept of a sweet-spot dose plays out on tirzepatide, understanding the Mounjaro fifth dose offers useful context for comparison.

Log every stage of your Wegovy journey — doses, side effects, and how you feel week by week — with GLP Trackr. Available free on the App Store and Google Play, with a 7-day trial to get started.